AARHUS, Denmark, July 4, 2013 /CNW/ - Unisense FertiliTech, world leader
in time-lapse technology for IVF announce they will present a large
scale analysis of embryo development variables which are linked to
implantation potential at the European Society of Human Reproduction
and Endocrinology (ESHRE) in London July 7th until 10th. These results will be presented at the Unisense FertiliTech exhibit.
Many clinics using the EmbryoScope™ time-lapse system provide
information about embryo development and clinical treatment outcome to
Unisense FertiliTech´s database. This database is the largest of its
kind and contains detailed information on embryo development
characteristics in relation to implantation and successful pregnancy.
Based on an agreement with 40 clinics comprising 12,000 transferred
embryos, a detailed analysis of 8,000 embryos with known implantation
outcome was performed. The analysis revealed clear variables, which
could be used to help select better embryos for day 2, 3 or 5 transfer.
Furthermore, the strength of the aneuploidy risk algorithm, recently
reported by the CARE Fertility group in the journal RBMonline (Campbell
et al, Reprod.Biomed. Online 2013 May; 26(5):477-85.) was tested against a large dataset and it
confirmed the findings.
Bjørn Molt Petersen and Mette Lægdsmand, data analysis experts at
FertiliTech, state "Although this analysis appears to show convincing
trends that are linked to embryo development potential, the analysis
also reveals the impact of different culture conditions and practices
between clinics. This means that the actual criteria for good embryo
quality needs to be individually validated prior to use".
Unisense FertiliTech who celebrates 10 years in developing innovative
technologies to improve embryo selection in the IVF laboratory has
developed and manufactures the EmbryoScope™ time-lapse system. The
system was cleared for clinical use in Europe in 2009 and is the only
time-lapse system which is FDA cleared for clinical use in the USA.
The technology is used in routine clinical practice by more than 275
clinics worldwide and has been used in approximately 60,000 treatment
cycles. It is estimated that more than 10,000 babies have been born
using the EmbryoScope™ system.
In order to allow clinics to utilize the full potential of time-lapse
technology, Unisense FertiliTech continues to develop embryo analysis
software to improve outcomes in IVF. Chief Scientific Officer Niels
Birger Ramsing states "very early on, we recognized the need for
software tools which will allow clinics to customize their own
evaluation models in their clinics, that is why we are at the forefront
of delivering such tools to help our customers make the best
About Unisense FertiliTech A/S:
Unisense FertiliTech A/S was founded in 2003 to develop technology to improve human embryo assessment in assisted reproduction. Unisense
FertiliTech has developed, and manufactures the EmbryoScope™ time-
lapse system, facilitating improved IVF treatment, flexible work
routines and effective communication through comprehensive
documentation of embryo development and evolving improvements in
selection. The System is FDA 510(k) cleared and CE marked as a Class II medical
Our Mission is to help infertile couples achieve their dream of parenthood through
development of novel technology, quantification and digitized
documentation. "The Vision to Conceive"
Unisense FertiliTech A/S
SOURCE: Unisense FertiliTech A/S
For further information:
Francesca Bahr, Email: firstname.lastname@example.org, +45 89449500